LSTA1
- Generic Name
- LSTA1
- Drug Type
- Biotech
- CAS Number
- 1392278-76-0
- Unique Ingredient Identifier
- Z8MXU5GH4Q
Intraperitoneal LSTA1 in CRS-HIPEC
Phase 1
Withdrawn
- Conditions
- Colorectal CancerOvarian CarcinomaAppendix CancerPeritoneal Metastases
- Interventions
- Procedure: CRS-HIPEC alone
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- University of California, San Diego
- Registration Number
- NCT06216561
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Phase 2
Active, not recruiting
- Conditions
- CholangiocarcinomaIntrahepatic CholangiocarcinomaGall Bladder CancerGallbladder CancerExtrahepatic CholangiocarcinomaBile Duct CancerGall Bladder CarcinomaGallbladder Carcinoma
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05712356
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
Active, not recruiting
- Conditions
- Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 158
- Registration Number
- NCT05042128
- Locations
- 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Brisbane and Womens Hospital, Herston, Queensland, Australia
🇦🇺Flinders Medical Centre, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath